Michael Serzan, MD

Author

Latest Articles
ESMO 2025 Updates in Prostate Cancer: Advances in Radioligand, Genomic, and AR-Targeted Therapies

Article

ESMO 2025 Updates in Prostate Cancer: Advances in Radioligand, Genomic, and AR-Targeted Therapies

Michael Serzan, MD

Latest Videos
New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Video

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Albert Jang, MD | Michael Serzan, MD

Highlights From the AMPLITUDE Study at ASCO 2025

Video

Highlights From the AMPLITUDE Study at ASCO 2025

Albert Jang, MD | Michael Serzan, MD

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Video

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Albert Jang, MD | Michael Serzan, MD

NIAGARA Trial: A New Standard of Care in MIBC

Video

NIAGARA Trial: A New Standard of Care in MIBC

Petros Grivas, MD, PhD | Michael Serzan, MD

The Future of Sacituzumab Govitecan in Metastatic Urothelial Cancer

Video

The Future of Sacituzumab Govitecan in Metastatic Urothelial Cancer

Michael Serzan, MD | Petros Grivas, MD, PhD